Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.
Mol Ther
; 25(11): 2533-2545, 2017 11 01.
Article
en En
| MEDLINE
| ID: mdl-28803862
ABSTRACT
Successful vaccination against cancer and infectious diseases relies on the induction of adaptive immune responses that induce high-titer antibodies or potent cytoxic T cell responses. In contrast to humoral vaccines, the amplification of cellular immune responses is often hampered by anti-vector immunity that either pre-exists or develops after repeated homologous vaccination. Replication-defective lymphocytic choriomeningitis virus (LCMV) vectors represent a novel generation of vaccination vectors that induce potent immune responses while escaping recognition by neutralizing antibodies. Here, we characterize the CD8 T cell immune response induced by replication-defective recombinant LCMV (rLCMV) vectors with regard to expansion kinetics, trafficking, phenotype, and function and we perform head-to-head comparisons of the novel rLCMV vectors with established vectors derived from adenovirus, vaccinia virus, or Listeria monocytogenes. Our results demonstrate that replication-deficient rLCMV vectors are safe and ideally suited for both homologous and heterologous vaccination regimens to achieve optimal amplification of CD8 T cell immune responses in vivo.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Linfocitos T Citotóxicos
/
Vacunación
/
Vectores Genéticos
/
Inmunidad Celular
/
Virus de la Coriomeningitis Linfocítica
Límite:
Animals
Idioma:
En
Año:
2017
Tipo del documento:
Article